Elamipretide Should NOT Be Used for Routine CKD Treatment
Elamipretide is not recommended for chronic kidney disease management, as it is not included in current evidence-based CKD treatment guidelines and lacks robust clinical trial data demonstrating efficacy for CKD outcomes. The KDIGO 2024 guidelines provide clear, evidence-based recommendations for CKD pharmacotherapy that do not include elamipretide 1.
Current Evidence-Based CKD Treatment Framework
The established therapeutic approach for CKD prioritizes medications with proven mortality and morbidity benefits:
First-Line Therapies (Strong Evidence)
SGLT2 inhibitors for patients with eGFR ≥20 ml/min/1.73 m² and either:
RAS inhibitors (ACEi/ARB) for patients with:
Nonsteroidal MRAs for select patients with type 2 diabetes, eGFR >25 ml/min/1.73 m², and persistent albuminuria despite RASi (2A) 1
Why Elamipretide Is Not Recommended
Limited and Contradictory Evidence
The available research on elamipretide for kidney disease reveals significant limitations:
Preclinical data only for diabetic kidney disease: One animal study showed elamipretide reduced albuminuria and mesangial matrix accumulation in db/db mice 2, but this has not translated to human CKD trials.
Single small human trial in a specific population: The only human kidney study involved just 14 patients with atherosclerotic renal artery stenosis undergoing stent revascularization—a highly specific scenario, not general CKD 3. This was a phase 2a trial examining procedural protection, not chronic disease management.
Recent negative data in related conditions: A 2026 study in HFpEF (a condition often comorbid with CKD) showed elamipretide improved mitochondrial respiration but failed to translate into functional benefits and showed mild decline in systolic performance 4. This raises concerns about clinical efficacy despite biochemical effects.
FDA approval limited to Barth syndrome: Elamipretide received accelerated FDA approval in 2025 specifically for Barth syndrome, a rare mitochondrial disorder—not for CKD 5. Notably, even in the Barth syndrome trial, there was no significant improvement in the primary endpoint (6-minute walk test), and approval was based on open-label extension data requiring confirmatory trials.
Critical Distinction: Mechanism vs. Clinical Benefit
While elamipretide's mechanism (cardiolipin binding, mitochondrial stabilization) is scientifically interesting 6, 7, mitochondrial dysfunction is not the primary therapeutic target in CKD management. The proven therapies work through:
- Hemodynamic modulation (RASi)
- Glucose-independent renoprotection (SGLT2i)
- Aldosterone antagonism (MRA)
These have demonstrated reductions in kidney failure, cardiovascular events, and mortality in large randomized trials—outcomes that elamipretide has not shown for CKD.
Common Pitfalls to Avoid
Do not substitute experimental therapies for proven treatments: Patients with CKD should receive guideline-directed therapy with SGLT2i, RASi, and potentially MRA based on their specific profile 1
Do not confuse preclinical promise with clinical evidence: Animal studies and mechanistic data do not justify clinical use without human trial validation
Do not extrapolate from other conditions: Elamipretide's approval for Barth syndrome does not support its use in CKD, which has entirely different pathophysiology
Clinical Algorithm for CKD Pharmacotherapy
For any patient with CKD, prioritize in this order:
- Assess for SGLT2i eligibility (eGFR ≥20, presence of diabetes, albuminuria ≥200 mg/g, or heart failure)
- Initiate RASi if albuminuria present (A2 or A3)
- Consider nonsteroidal MRA if type 2 diabetes with persistent albuminuria despite RASi and SGLT2i, eGFR >25, and normal potassium
- Optimize blood pressure control and manage cardiovascular risk factors
Elamipretide has no role in this algorithm based on current evidence.